Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

3D-Printed Pharmaceuticals: Customized Dosing, Polypills, and On-Demand Drug Manufacturing :Review article

V Suryanarayanan[1*] , S Yogeshwari[2] , M Kavya[3] , Dr. M.K. Sundar Sri[4], Dr. Karthickeyan krishnan[5], Dr. Palani shanmugasundaram[6]

[1*]Pharm.D Intern, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117, India.
[2]Pharm.D Intern, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117, India.
[3]Pharm.D Intern, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117, India.
[4] Assistant Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117, India.
[5]Professor and Head, Department of Pharmacy Practice, School of Pharmaceutical Sciences,Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117, India.
[6]Dean, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai, TN-600117.

*Corresponding Author
V Suryanarayanan

Article History
Received: 22.09.2025
Revised: 30.09.2025
Accepted: 17.10.2025
Published: 05.11.2025

Abstract: 3D printing, or additive manufacturing, has revolutionized multiple industries, and its application in pharmaceuticals offers promising avenues for personalized medicine. This review explores recent advancements in 3D-printed pharmaceuticals, emphasizing customized dosing, polypill formulations, and the potential for on-demand drug manufacturing. These innovations aim to enhance therapeutic outcomes, improve Additive manufacturing or 3D printing has the potential to revolutionize the pharmaceuticals sector by facilitating the feasible implementation of personalized medicine. The capability to customize a medication's dose to meet a patient's unique requirements—e.g., for pediatric, geriatric, or pharmacogenomics-guided therapy—remedies an essential weakness of the conventional "one-size-fits-all" model, and could increase therapeutic effectiveness and safety. The potential for decentralized, demand-based manufacturing in pharmacies or even hospitals could change supply chains, enabling instant production of individual drugs or customized formulations according to urgent clinical demand. In spite of this encouraging potential, however, the general clinical use of 3D-printed medicines is currently confronted by significant challenges. Among these are the creation of a robust regulatory environment for decentralized production, assuring scalability of the printing process, and broadening the library of pharmaceutically-approved, biocompatible printing materials. This review meets these challenges by highlighting the compelling opportunities they create for future science, technology development, and integration into the mainstream of clinical practice. dication adherence, and facilitate decentralized production. Challenges such as regulatory hurdles, scalability, and material constraints are also discussed, along with prospects for future research and clinical implementation.

Keywords:

INTRODUCTION

Conventional drug production is inherently rooted in a "one-size-fits-all" strategy, where medicines are mass-produced in a few fixed dosages. Although economical, this mass production technique rarely caters to the complex individual requirements of patients. Age, weight, genetics, renal and hepatic function, and comorbidities are all known factors that can greatly influence the pharmacokinetics and pharmacodynamics of a drug, causing suboptimal efficacy or toxicity in most people. The advent of 3D printing technology, or additive manufacturing, in the pharmaceutical industry presents an innovative platform for advancing truly individualized therapy. Through its ability to provide accurate control of the dose, release profile, and combination of several active pharmaceutical ingredients into one unit, 3D printing can revolutionize personalized medicine. With the transition from batch manufacturing to digital fabrication, dosage forms can be produced in a way that is customized to the individual physiological and clinical needs of an individual patient, which represents a major departure from traditional approaches (Norman et al., 2017).

2. Technologies in 3D Pharmaceutical Printing

The versatility of different 3D printing methods is crucial to their suitability for drug production. Each technique has particular strengths suitable for specific applications in the pharmaceutical industry.

Fused Deposition Modeling (FDM): One of the most common methods. It utilizes drug-filled thermoplastic filaments (e.g., PLA, PVA) that are melted and extruded layer by layer to form the dosage form. A key pre-processing process, Hot-Melt Extrusion (HME), is commonly employed to evenly disperse the API in the polymer matrix to form the filament. FDM permits the control of drug release through adjustment of the infill geometry and density of the tablet (Goyanes et al., 2015).

Binder Jetting (Inkjet Printing): This contactless process prints accurate droplets of a drug-formulating "ink" or a liquid binder onto a bed of powder. It is well

suited for the manufacture of low-dose, high-potency medicines and for the quick development of complex forms. It has the capability to produce highly porous structures for fast dissolution or accurate multi-layer structures (Sadia et al., 2016).

Selective Laser Sintering (SLS): SLS involves the use of a laser to selectively sinter particles of powdered polymer and API. SLS offers the chief benefit of being able to produce complex, high-resolution geometries without the use of solvents or binders. This qualifies it for the creation of dosage forms with advanced internal geometries that regulate release kinetics (Fina et al., 2018).

Stereolithography (SLA): SLA utilizes a laser to cure liquid resin formulations layer by layer. It has superior resolution and surface finish. In pharmaceuticals, this would mean the creation of biocompatible, photocurable resins which can accommodate drugs without affecting their stability or the printing process (Khaled et al., 2014).

The method chosen will depend on the target drug release profile, the printability of the API and the target structural complexity of the final drug product.

3. Customized Dosing

The ability to provide individualized dosing is perhaps the most obvious advantage of pharmaceuticals printed using 3D printing. Individualized dosing is essential in susceptible populations:

Pediatrics: Children's dosing is usually weight or body surface area related and must often be accomplished by splitting adult tablets, resulting in inaccuracies and lack of stability. 3D printing can create small lots of precise-strength tablets or chewable tablets in any desired dose (e.g., 12.5 mg, 37 mg).

Titration & Geriatrics: Older patients may need to be dose titrated cautiously on agents such as warfarin or levodopa. 3D printing can create an incremental dose series (e.g., 1 mg, 2 mg, 5 mg) from a single feedstock, making titration easier and safer.

This is done by digitally modifying the design file. For example, in FDM, the concentration of drug in the filament can be set, and the dose is regulated through changes in the volume (and thus the mass) of the printed object. This digital control eliminates human compounding error and gives a degree of dosing accuracy that was not possible with traditional manufacturing (Alhnan et al., 2016).

4. Polypills: Multi-Drug Formulations

Polypills, which are single tablets with multiple active pharmaceutical ingredients (APIs), pose significant convenience and compliance advantages for patients who have to take care of multiple chronic diseases, including hypertension, diabetes, and dyslipidemia. 3D printing advances the polypill idea by making it possible to separate spatially and separately program different drug release profiles within a single tablet.

Compartmentalization: Segments of a tablet can be printed using various APIs and excipients. This physically differentiates incompatible drugs and enables each compartment to be tailored for a particular release profile (e.g., immediate release, delayed release, or sustained release).

Programmable Release: A classic example is a multi-layered polypill where one drug releases immediately when taken, and a second drug in a different layer releases after a programmed delay, coordinating therapy with circadian body rhythms or clinical requirements. This kind of control can reduce drug-drug interactions, maximize pharmacokinetics, and greatly enhance patient compliance by decreasing pill burden (Skowyra et al., 2015; Goyanes et al., 2015).

5. On-Demand Drug Manufacturing

3D printing makes possible a transition from centralized mass production to decentralized on-demand production of drugs. This revolution has far-reaching implications:

Decentralized Production: Hospital pharmacies or even community pharmacies might serve as mini-manufacturing sites. A doctor could send a digital prescription file, and a pharmacist could print the customized medication in hours.

Crisis Response: Within remote regions, disaster areas, or the case of supply chain interruption, localized production of critical medications provides uninterrupted access to therapy. This is also being developed for long-duration missions to space, where the capacity to make drugs en route would be essential (Norman et al., 2017).

Rare Diseases & Orphan Drugs: This paradigm is financially sound for making limited quantities of drugs for orphan diseases, which are usually not profitable for mainstream large-scale producers (Jamróz et al., 2018).

6. Regulatory and Technical Challenges

In spite of its revolutionary promise, clinical use of 3D-printed medicines on a broad scale is hindered by considerable obstacles.

Regulatory Uncertainty: Organizations such as the FDA and EMA are already working on developing guidelines for this novel manufacturing model. Some of the challenges involve batch-to-batch and printer-to-printer consistency, confirming the stability of drugs manufactured in small batches, and defining "good manufacturing practice" (GMP) regulations for decentralized, digital manufacturing (Norman et al., 2017).

Compatibility of Materials: The range of pharmaceutically accepted, biocompatible polymers and excipients for use in 3D printing is limited. Much work has to be done to create printable materials that are able to withstand the printing process (e.g., hot temperatures in FDM) without degrading the API or losing their functional properties (Sadia et al., 2016).

Scalability and Cost: Although ideal for on-demand production, the challenge of scaling 3D printing to match the throughput of high-speed tableting presses to produce mass-market drugs still persists. The initial high cost of GMP-compliant printers and the present slow rates of printing are major impediments to large-scale commercialization.

7. Future Directions

To realize the full potential of 3D-printed drugs, efforts in the future need to be focused on:

Material Science: Accelerating the creation of a broader array of "GRAS" and pharmacopoeia-validated printable materials.

Digital Integration: Designing intelligent software platforms that are capable of easily integrating patient-specific information (from electronic health records, genetic analysis) to automatically create and verify personalized drug blueprint files.

Harmonization of Regulation: Defining clear, globally harmonized regulatory frameworks and standards of quality control for the approval and post-market monitoring of 3D-printed medicines. Advanced Manufacturing: Creating faster, multi-material printers with GMP-level manufacturing capacity. The interconnecting of 3D printing with other Industry 4.0 technologies, including Artificial Intelligence (AI) for predictive drug design and the Internet of Things (IoT) for printer performance remote monitoring, will continue to optimize and tailor medication therapies.

CONCLUSION

Pharmaceutical 3D printing is a paradigm shift from batch production to personalized, digital manufacturing. It provides a breakthrough methodology of medicine for enabling tailored dosing for precision therapy, advanced polypills for improved adherence, and decentralized on-demand manufacturing for responsive healthcare. While significant technical and regulatory challenges remain, continued research, inter-disciplinary collaboration, and forward-thinking regulatory involvement are progressively making the way for clinical adoption. The convergence of digital health, advanced manufacturing, and patient-centered care holds the promise of launching a new era of precision pharmacotherapy that will lead to more effective and safer care for all patients.

REFERENCES

1. Alhnan, M. A., et al. (2016). Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharmaceutical Research, 33(8), 1817–1832.
2. Fina, F., et al. (2018). Selective laser sintering (SLS) 3D printing of medicines. International Journal of Pharmaceutics, 529(1-2), 285–293.
3. Goyanes, A., et al. (2015). Personalized 3D printed medicines: Preparation of a multi-layered polypill containing six drugs using a novel 3D printer. Future Medicinal Chemistry, 7(7), 847–853.
4. Jamróz, W., et al. (2018). 3D printing in pharmaceutical and medical applications – recent achievements and challenges. Pharmaceutical Research, 35(9), 176.
5. Khaled, S. A., et al. (2014). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. Journal of Controlled Release, 217, 308–314.
6. Norman, J., et al. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews, 108, 39–50.
7. Sadia, M., et al. (2016). Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. International Journal of Pharmaceutics, 513(1-2), 659–668.
8. Skowyra, J., et al. (2015). Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. European Journal of Pharmaceutical Sciences, 68, 11–17.